CV Sciences, Inc. (CVSI) Stock

About CV Sciences, Inc.

CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.

CV Sciences, Inc. is headquartered in US.

CV Sciences, Inc. (CVSI) stock trades at $0.02 with a market capitalization of $4.08M. The stock is valued at a price-to-earnings (P/E) ratio of -2.50, price-to-book of 2.50, price-to-sales of 0.30. Over the past 52 weeks the stock has ranged between $0.02 and $0.10, and currently trades 80.0% below its 52-week high.

On profitability, CV Sciences, Inc. generates a return on equity (ROE) of -94.61%, return on capital employed of -85.67%, an operating margin of -9.87%, a net profit margin of -11.15%.

Official website: www.cvsciences.com